Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, United States
Victoria Zyulina
Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, United States; Department of Microbiology and Immunology, Weill Cornell Medical College, New York, United States
Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, United States
Marija Dacic
David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery Research Institute, New York, United States; Arthritis and Tissue Degeneration Program, Hospital for Special Surgery Research Institute, New York, United States; Physiology, Biophysics, and Systems Biology Program, Weill Cornell Graduate School of Medical Sciences, New York, United States
Yurii Chinenov
David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery Research Institute, New York, United States
Andrea R Daamen
Department of Medicine, AMPEL BioSolutions, Charlottesville, United States
Keila R Veiga
Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, United States; Pediatric Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States; Department of Pediatrics, Weill Cornell Medical College, New York, United States
Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, United States; Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States
David J Oliver
David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery Research Institute, New York, United States
Pamela Cabahug-Zuckerman
Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, United States
Jose Lora
Arthritis and Tissue Degeneration Program, Hospital for Special Surgery Research Institute, New York, United States; Physiology, Biophysics, and Systems Biology Program, Weill Cornell Graduate School of Medical Sciences, New York, United States
Department of Dermatology, Weill Cornell Medical College, New York, United States
William D Shipman
Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, United States; Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program, Weill Cornell Medical College, New York, United States; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, United States
William G Ambler
Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, United States; Pediatric Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States; Department of Pediatrics, Weill Cornell Medical College, New York, United States
Sarah F Taber
Pediatric Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States; Department of Pediatrics, Weill Cornell Medical College, New York, United States
Karen B Onel
Pediatric Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States; Department of Pediatrics, Weill Cornell Medical College, New York, United States
Department of Dermatology, Weill Cornell Medical College, New York, United States
Mehdi Rashighi
Department of Dermatology, University of Massachusetts Medical School, Worcester, United States
James G Krueger
Laboratory of Investigative Dermatology, Rockefeller University, New York, United States
Niroshana Anandasabapathy
Department of Dermatology, Weill Cornell Medical College, New York, United States; Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program, Weill Cornell Medical College, New York, United States; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, United States
Department of Microbiology and Immunology, Weill Cornell Medical College, New York, United States; David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery Research Institute, New York, United States; Arthritis and Tissue Degeneration Program, Hospital for Special Surgery Research Institute, New York, United States; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, United States
Ali Jabbari
Laboratory of Investigative Dermatology, Rockefeller University, New York, United States
Carl P Blobel
Arthritis and Tissue Degeneration Program, Hospital for Special Surgery Research Institute, New York, United States; Physiology, Biophysics, and Systems Biology Program, Weill Cornell Graduate School of Medical Sciences, New York, United States; Department of Physiology, Biophysics, and Systems Biology, Weill Cornell Medical College, New York, United States
Peter E Lipsky
Department of Medicine, AMPEL BioSolutions, Charlottesville, United States
Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, United States; Department of Microbiology and Immunology, Weill Cornell Medical College, New York, United States; Pediatric Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States; Department of Pediatrics, Weill Cornell Medical College, New York, United States; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, United States
The autoimmune disease lupus erythematosus (lupus) is characterized by photosensitivity, where even ambient ultraviolet radiation (UVR) exposure can lead to development of inflammatory skin lesions. We have previously shown that Langerhans cells (LCs) limit keratinocyte apoptosis and photosensitivity via a disintegrin and metalloprotease 17 (ADAM17)-mediated release of epidermal growth factor receptor (EGFR) ligands and that LC ADAM17 sheddase activity is reduced in lupus. Here, we sought to understand how the lupus skin environment contributes to LC ADAM17 dysfunction and, in the process, differentiate between effects on LC ADAM17 sheddase function, LC ADAM17 expression, and LC numbers. We show through transcriptomic analysis a shared IFN-rich environment in non-lesional skin across human lupus and three murine models: MRL/lpr, B6.Sle1yaa, and imiquimod (IMQ) mice. IFN-I inhibits LC ADAM17 sheddase activity in murine and human LCs, and IFNAR blockade in lupus model mice restores LC ADAM17 sheddase activity, all without consistent effects on LC ADAM17 protein expression or LC numbers. Anti-IFNAR-mediated LC ADAM17 sheddase function restoration is associated with reduced photosensitive responses that are dependent on EGFR signaling and LC ADAM17. Reactive oxygen species (ROS) is a known mediator of ADAM17 activity; we show that UVR-induced LC ROS production is reduced in lupus model mice, restored by anti-IFNAR, and is cytoplasmic in origin. Our findings suggest that IFN-I promotes photosensitivity at least in part by inhibiting UVR-induced LC ADAM17 sheddase function and raise the possibility that anifrolumab ameliorates lupus skin disease in part by restoring this function. This work provides insight into IFN-I-mediated disease mechanisms, LC regulation, and a potential mechanism of action for anifrolumab in lupus.